Embecta Corp./$EMBC
1D1W1MYTD1Y5YMAX
Capital at risk
About Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
- Ticker
- $EMBC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,850
- Headquarters
- Parsippany, United States
- Website
- www.embecta.com
Embecta Corp. Metrics
BasicAdvanced
$320M
3.84
$1.47
0.85
$0.32
0.71%
Price and volume
Market cap
$320M
Beta
0.85
52-week high
$14.91
52-week low
$2.77
Average daily volume
1.2M
Dividend rate
$0.32
Financial strength
Current ratio
1.68
Quick ratio
0.945
Long term debt to equity
-2.207
Total debt to equity
-2.451
Dividend payout ratio (TTM)
31.09%
Interest coverage (TTM)
2.36%
Profitability
EBITDA (TTM)
278.1
Gross margin (TTM)
58.85%
Net profit margin (TTM)
8.59%
Operating margin (TTM)
22.96%
Effective tax rate (TTM)
30.00%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
12.07%
Return on equity (TTM)
-13.65%
Valuation
Price to earnings (TTM)
3.845
Price to revenue (TTM)
0.326
Price to book
-0.52
Price to tangible book (TTM)
-0.46
Price to free cash flow (TTM)
2.017
Free cash flow yield (TTM)
49.57%
Free cash flow per share (TTM)
2.801
Dividend yield (TTM)
5.66%
Forward dividend yield
0.71%
Growth
Revenue change (TTM)
-7.60%
Earnings per share change (TTM)
3.42%
3-year revenue growth (CAGR)
-2.92%
3-year earnings per share growth (CAGR)
21.14%
3-year dividend per share growth (CAGR)
-8.48%
What the Analysts think about Embecta Corp.
Analyst ratings (Buy, Hold, Sell) for Embecta Corp. stock.
Analyst projections of the future price of Embecta Corp. stock.
Bulls say / Bears say
Third-quarter performance improved sharply from the weak second quarter: revenue rose by about $50 million sequentially, while management raised its full-year adjusted operating-margin guidance to 23.5–24.0% and adjusted EPS guidance to $1.80–$1.90. This suggests cost controls are helping protect earnings even before sales recover. (Embecta, The Motley Fool)
Embecta is using the Owen Mumford acquisition to move beyond its declining insulin-delivery base. The deal adds the Aidaptus auto-injector platform and access to chronic-care and pharmaceutical drug-delivery markets, while Embecta says generic GLP-1 therapies using its pen needles have already launched in several countries. (Embecta, The Motley Fool)
Cash generation is still giving Embecta room to repair its balance sheet. It repaid about $128 million of debt in the first nine months of fiscal 2026, expects at least $150 million for the year, and extended $210 million of revolving-credit commitments to December 2028. (The Motley Fool, StockTitan)
The core US franchise is deteriorating quickly. Third-quarter US revenue fell 24.6% year on year, while overall revenue declined 8.1%; management’s full-year revenue guidance still implies a 4.2–6.1% decline. (Embecta, MarketScreener)
Falling volume and pricing are putting heavy pressure on profitability. In the third quarter, gross margin dropped to 56.4% from 66.7%, adjusted EBITDA margin fell to 31.5% from 44.3%, and net income was down 53.6% year on year. (Embecta, StockTitan)
Leverage remains a major constraint while Embecta funds its diversification. The company had $1.469 billion of debt principal against $218.2 million of cash and restricted cash after borrowing for Owen Mumford, and S&P Global downgraded its credit rating to B because weaker demand was expected to push leverage higher. (StockTitan, S&P Global Ratings)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
Embecta Corp. Financial Performance
Revenues and expenses
Embecta Corp. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Embecta Corp. News
AllArticlesVideos
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp1 month ago
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp2 months ago
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Business Wire2 months ago
Funds containing Embecta Corp.
AllEURGBP
Fund name | Fund size | $EMBC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.